Strategies currently under development are extensively reviewed by Mu et al. [152] and include but are not limited to (i) drug-carrying liposomes and micro-/nanoparticles, which are phagocytosed by BM macrophages or (ii) which are modified to bind with high affinity to the bone mineral; furthermore (iii) antibody-conjugated immunocytokines such as IL2 can be targeted to antigens of the neoangiogenic tumor vasculature in the BM, an approach currently evaluated in a phase I/II trial for solid tumors [153]. Here, IL2 is linked to neoplasm.